488 related articles for article (PubMed ID: 32924198)
21. Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study.
Miao J; Wang L; Ong EHW; Hu C; Lin S; Chen X; Chen Y; Zhong Y; Jin F; Lin Q; Lin S; Hu X; Zhang N; Wang R; Wang C; Guo X; Yit NLF; Shi H; Tan SH; Mai H; Xie C; Chua MLK; Zhao C
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):815-825. PubMed ID: 36872457
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2-3-positive nasopharyngeal carcinoma patients.
Tao HY; Liu H; He F; He CX; Li R; Du KP; Yuan YW; Zheng RH
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2959-2969. PubMed ID: 34822015
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Chen YP; Wang ZX; Chen L; Liu X; Tang LL; Mao YP; Li WF; Lin AH; Sun Y; Ma J
Ann Oncol; 2015 Jan; 26(1):205-211. PubMed ID: 25355717
[TBL] [Abstract][Full Text] [Related]
24. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
25. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
26. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
Fountzilas G; Ciuleanu E; Bobos M; Kalogera-Fountzila A; Eleftheraki AG; Karayannopoulou G; Zaramboukas T; Nikolaou A; Markou K; Resiga L; Dionysopoulos D; Samantas E; Athanassiou H; Misailidou D; Skarlos D; Ciuleanu T
Ann Oncol; 2012 Feb; 23(2):427-35. PubMed ID: 21525406
[TBL] [Abstract][Full Text] [Related]
27. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yu YH; Liang H; Liu GY; Xiang YQ; Guo X; Lv X
Oral Oncol; 2017 Jul; 70():7-13. PubMed ID: 28622892
[TBL] [Abstract][Full Text] [Related]
29. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
30. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
31. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
[TBL] [Abstract][Full Text] [Related]
32. The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.
Luo Y; Cai B; Li B; Liu F; Du L; Zhao D; Fan W; Meng L; Zhang X; Ma L
Technol Cancer Res Treat; 2022; 21():15330338221109974. PubMed ID: 35770295
[No Abstract] [Full Text] [Related]
33. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.
Li T; Yang F; Ma K; Lv L
Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538
[TBL] [Abstract][Full Text] [Related]
34. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
35. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre study.
Zhong L; Dong D; Fang X; Zhang F; Zhang N; Zhang L; Fang M; Jiang W; Liang S; Li C; Liu Y; Zhao X; Cao R; Shan H; Hu Z; Ma J; Tang L; Tian J
EBioMedicine; 2021 Aug; 70():103522. PubMed ID: 34391094
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.
Wang P; Zhang M; Ke C; Cai C
Medicine (Baltimore); 2020 Mar; 99(10):e19360. PubMed ID: 32150078
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
Xu W; Qiu L; Li F; Fei Y; Wei Q; Shi K; Zhu Y; Luo J; Wu M; Yuan J; Liu H; Mao J; Cao Y; Zhou S; Guan X
Oral Oncol; 2024 Jul; 154():106865. PubMed ID: 38823173
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
Nazeer F; Poulose JV; Kainickal CT
Cancer Treat Res Commun; 2022; 32():100589. PubMed ID: 35724627
[TBL] [Abstract][Full Text] [Related]
39. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
40. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]